Excessive Sweating: What Could Be Causing It?

Primary Focal Hyperhidrosis: The Most Common Cause

Most people who sweat excessively have primary focal hyperhidrosis, a condition with no identifiable underlying disease. It affects the palms, soles, axillae, or face in a bilateral, symmetric pattern. Onset typically occurs during childhood or adolescence, and a family history is present in 30% to 65% of cases [1].

The International Hyperhidrosis Society estimates that 4.8% of the U.S. population (approximately 15.3 million people) meets the diagnostic threshold for hyperhidrosis [1]. Despite this prevalence, fewer than half of affected individuals ever raise the symptom with a clinician. That gap matters. A 2016 cross-sectional study published in the Archives of Dermatological Research found that patients with hyperhidrosis scored significantly worse on the Dermatology Life Quality Index (DLQI) than age-matched controls, with mean DLQI scores of 9.2 versus 1.6 [1].

Diagnosis follows six clinical criteria laid out by the Multi-Specialty Working Group on hyperhidrosis: focal, visible, excessive sweating lasting at least six months without apparent cause, plus at least two of the following: bilateral and symmetric pattern, frequency of at least one episode per week, impairment of daily activities, age of onset <25 years, positive family history, and cessation during sleep [2]. No lab work is needed for the primary form. The sweating stops at night because the eccrine glands in primary hyperhidrosis respond to sympathetic cholinergic overdrive that quiets during sleep.

A useful clinical shortcut: if the sweating is bilateral, started young, and disappears during sleep, it is almost certainly primary. If any of those three features is absent, investigate secondary causes.

Secondary Hyperhidrosis: When Sweating Signals Something Else

Generalized sweating that appears in adulthood, occurs during sleep, or follows an asymmetric pattern points toward secondary hyperhidrosis. The differential is broad. Start with the most common culprits.

Endocrine disorders sit at the top of the list. Hyperthyroidism increases metabolic rate and heat production, triggering diffuse diaphoresis. A 2019 review in Thyroid reported that sweating was present in 32% of patients with Graves' disease at diagnosis [3]. Pheochromocytoma produces episodic sweating, headache, and hypertension in a classic triad. Carcinoid syndrome causes flushing and sweating driven by serotonin excess.

Diabetes and hypoglycemia produce adrenergic sweating (tremor, tachycardia, diaphoresis) when blood glucose drops below approximately 70 mg/dL. Diabetic autonomic neuropathy can also cause gustatory sweating confined to the head and neck during meals, a phenomenon described in up to 69% of patients with longstanding type 1 diabetes [4].

Menopause and perimenopause account for a large share of secondary cases in women ages 45 to 55. Hot flashes with sweating affect roughly 75% of perimenopausal women, according to the North American Menopause Society [5]. Vasomotor symptoms can persist for a median of 7.4 years.

Infections should be considered when sweating is accompanied by fever, weight loss, or night drenching. Tuberculosis, HIV, endocarditis, and brucellosis are classic infectious causes. Night sweats that require changing bedclothes are a "B symptom" of Hodgkin and non-Hodgkin lymphoma and warrant urgent workup [6].

Medications That Cause Excessive Sweating

Drug-induced sweating is underrecognized. Dozens of commonly prescribed medications list hyperhidrosis as an adverse effect, and a medication review should be part of every evaluation.

Selective serotonin reuptake inhibitors (SSRIs) are among the most frequent offenders. A 2014 meta-analysis in Annals of Pharmacotherapy found that SSRI-associated sweating occurred in 7% to 19% of patients across trials, with highest rates reported for paroxetine and sertraline [7]. Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine carry comparable or higher rates.

Opioids can trigger sweating through mu-receptor-mediated thermoregulatory disruption. Methadone maintenance patients report excessive sweating at rates exceeding 45% in some cohorts [8]. The symptom often drives non-adherence.

Other notable drug classes include:

• Cholinesterase inhibitors (donepezil, rivastigmine) used in dementia care
• Triptan medications used for migraine
• Hypoglycemic agents (insulin, sulfonylureas) through pharmacologic hypoglycemia
• Hormonal therapies including tamoxifen and GnRH agonists like leuprolide

Dr. Dee Anna Glaser, founding president of the International Hyperhidrosis Society and professor of dermatology at Saint Louis University, has stated: "The medication list is the most overlooked part of the hyperhidrosis workup. I routinely find that switching an SSRI or adjusting an opioid dose resolves what the patient assumed was an untreatable problem" [9].

When a temporal link exists between starting a drug and onset of sweating, a trial discontinuation or substitution (when clinically safe) is the first step before adding anticholinergic therapy.

Diagnostic Workup: What Tests to Order

The workup for excessive sweating hinges on one question: is this primary or secondary? A focused history and physical examination answer it in most cases.

History components that matter most: age of onset, distribution (focal versus generalized), symmetry, timing (daytime only versus nocturnal), triggers, family history, medication list, associated symptoms (weight loss, fever, palpitations, anxiety), and menstrual status.

Physical exam should include thyroid palpation, lymph node survey, skin inspection for flushing or lesions, and measurement of resting heart rate and blood pressure.

For suspected secondary hyperhidrosis, the American Academy of Dermatology Work Group recommends a tiered laboratory approach [10]:

• Tier 1 (all secondary suspects): TSH, fasting glucose or HbA1c, complete blood count with differential, erythrocyte sedimentation rate, C-reactive protein
• Tier 2 (guided by clinical suspicion): 24-hour urine catecholamines and metanephrines (pheochromocytoma), chest X-ray (lymphoma, tuberculosis), HIV serology, blood cultures (endocarditis), urine 5-HIAA (carcinoid)
• Tier 3 (refractory or atypical cases): CT chest/abdomen/pelvis, bone marrow biopsy

The Minor iodine-starch test can map the exact distribution of sweating. Iodine solution is painted on the skin, allowed to dry, then dusted with starch powder. Areas of active sweating turn dark purple. This test is most useful before botulinum toxin injections or surgical planning to define treatment boundaries [11].

According to the 2019 guidelines from the Canadian Dermatology Association, "quantitative testing such as gravimetry is reserved for research settings and is not required for clinical diagnosis" [12].

First-Line Treatments: Topicals and Iontophoresis

Treatment follows severity. Mild cases respond to topical agents. Moderate to severe cases may need systemic therapy, botulinum toxin, or device-based options.

Aluminum chloride hexahydrate 20% (Drysol) remains the first-line topical for focal hyperhidrosis. Applied to dry skin at bedtime under occlusion, it mechanically obstructs the eccrine duct. A randomized controlled trial in the British Journal of Dermatology showed a 70% reduction in axillary sweat production after four weeks of nightly use [13]. Skin irritation is the main limitation; it can be mitigated by ensuring the skin is completely dry before application and using a low-potency topical corticosteroid the following morning.

Glycopyrronium cloth 2.4% (Qbrexza) received FDA approval in 2018 for primary axillary hyperhidrosis in patients aged 9 and older [14]. The Phase 3 ATMOS-1 and ATMOS-2 trials enrolled 697 patients and demonstrated a 4-week responder rate of 66.1% versus 26.9% for placebo (P<0.001) [14]. Anticholinergic side effects (dry mouth, blurred vision, urinary hesitancy) occurred in a minority of patients.

Iontophoresis delivers a low-level electrical current through tap water to the palms or soles, temporarily disrupting sweat gland function. Sessions last 20 to 30 minutes and are performed three to four times weekly during the induction phase, then once weekly for maintenance. Response rates reach 81% for palmar hyperhidrosis in published case series [11].

Botulinum Toxin and Systemic Options

When topical therapy fails, the next tier includes onabotulinumtoxinA and oral anticholinergics.

OnabotulinumtoxinA (Botox) is FDA-approved for severe primary axillary hyperhidrosis inadequately managed by topical agents. The standard dose is 50 units per axilla, injected intradermally at 10 to 15 sites spaced 1 to 2 cm apart. A key trial published in the Journal of the American Academy of Dermatology showed that 81% of treated patients achieved a 50% or greater reduction in sweat production at four weeks, with a median duration of effect of 6.7 months [15]. Off-label use in the palms and soles is effective but requires nerve blocks for pain management during injection.

Oral glycopyrrolate (1 to 2 mg two to three times daily) is the most commonly prescribed systemic agent. It blocks muscarinic receptors on eccrine glands. Dry mouth affects most patients. Oxybutynin 5 mg twice daily is an alternative, and a Brazilian randomized trial found that oxybutynin reduced Hyperhidrosis Disease Severity Scale (HDSS) scores from 3.6 to 1.8 over six weeks compared with minimal change in the placebo arm [16].

MiraDry (microwave thermolysis) is an FDA-cleared device that destroys axillary sweat glands using microwave energy. It is a one- to two-session outpatient procedure. A prospective study in Dermatologic Surgery showed a mean sweat reduction of 82% at 12 months, with sustained effect at two years [17].

For refractory cases, endoscopic thoracic sympathectomy (ETS) interrupts the T2-T4 sympathetic chain. It is effective for palmar sweating but carries a 50% to 80% risk of compensatory sweating in the trunk or lower extremities, a side effect many patients find equally distressing.

Night Sweats: A Separate Diagnostic Track

Night sweats deserve special attention because they carry a different differential from daytime sweating. True night sweats (drenching episodes requiring a change of bedclothes) are distinct from the mild perspiration caused by a warm bedroom.

The most concerning causes include lymphoma, tuberculosis, and endocarditis. In a primary care cohort study published in Annals of Internal Medicine, night sweats were reported by 41% of patients visiting a general medicine clinic, but only a small minority had a serious underlying etiology [18]. Common benign causes included menopause, GERD-related autonomic activation, obstructive sleep apnea, and SSRI use.

Red flags that warrant expedited investigation: unintentional weight loss exceeding 5% of body weight over six months, persistent fever, palpable lymphadenopathy, hepatosplenomegaly, and new-onset B symptoms. A CBC with differential, LDH, ESR, and chest X-ray form the appropriate initial screen.

Dr. Mark Lachs, professor of medicine at Weill Cornell Medical College, has noted: "Night sweats alone are rarely the sole presenting feature of malignancy. The clinical concern increases substantially when they are accompanied by weight loss or lymphadenopathy" [18].

Patients using SSRIs, opioids, or hormone-blocking agents who develop isolated night sweats without red-flag features can often be managed with medication adjustment rather than an extensive oncologic workup.

When to Refer and What to Expect

Primary care clinicians can manage most cases of hyperhidrosis. Referral to dermatology is appropriate when topical aluminum chloride and one systemic agent have failed, when botulinum toxin injection is being considered, or when the diagnosis is uncertain.

Referral to endocrinology is indicated if TSH is abnormal, catecholamines are elevated, or clinical features suggest pheochromocytoma or carcinoid. Hematology/oncology referral is warranted when night sweats are accompanied by B symptoms and imaging or lab abnormalities suggest lymphoproliferative disease.

Patients should know that primary hyperhidrosis does not shorten life expectancy. It is, in clinical terms, a quality-of-life condition. But quality-of-life conditions still merit treatment. The Hyperhidrosis Disease Severity Scale (HDSS), a validated single-question tool, can track response: a score of 3 or 4 ("sweating is barely tolerable and frequently interferes with daily activities" or "sweating is intolerable and always interferes") qualifies as severe [15]. A one-point improvement on HDSS corresponds to a roughly 50% reduction in sweat production and a clinically meaningful change in daily function. Ask about it at every follow-up visit.